Description: Viva Biotech Holdings provides structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company offers its drug discovery services using its structure-based drug discovery, fragment-based drug discovery, affinity selection mass spectrometry screening, and membrane protein targeted drug discovery platforms. It offers gene-to-protein and gene-to-structure, viva engine for lead discovery, membrane protein targeted discovery technology, medicinal chemistry, in vitro pharmacology, and antibody discovery services. The company primarily develops cell lines, crystal structures, GPCR proteins, antibodies, and proteins. Viva Biotech Holdings was founded in 2008 and is headquartered in Shanghai, China.
Home Page: www.vivabiotech.com.cn
No.735, Ziping Road
Shanghai,
201318
China
Phone:
86 21 6089 3288
Officers
| Name | Title |
|---|---|
| Dr. Chen Cheney Mao Ph.D. | Chairman & CEO |
| Dr. Delin Ren Ph.D. | Pres & Exec. Director |
| Mr. Zheren Wang C.F.A. | Chief Financial Officer |
| Mr. Xueheng Cheng Ph.D. | Chief Technology Officer |
| Dr. Zhixiong Ye Ph.D. | Chief Scientific Officer |
| Mr. Ying Wu M.B.A. | Exec. VP & Exec. Director |
| Mr. Han Dai Ph.D. | CIO & Head of Viva BioInnovator |
| Mr. Jianhua Cai Ph.D. | Sr. VP |
| Jianguo Ma Ph.D. | Sr. VP & CEO of Langhua Pharmaceutical |
| Mr. Xianyong Bu Ph.D. | Sr. VP |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 20.05 |
| Price-to-Book MRQ: | 0.6553 |
| Price-to-Sales TTM: | 0.2084 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 2309 |